Pfizer Inc (PFE) 30.59 $PFE
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 46.70 (+0.06), PFE: 30.59 (+0.27), BIOD: 1.61 (+0.02)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 43.53 (+0.61), KMI: 40.41 (+0.16), GE: 27.01 (+0.40), F: 15.50 (-0.04), ABX.TO: 15.04 (+0.97), K.TO: 3.37 (+0.32), ABX: 13.29 (+0.82), KGC: 2.96 (+0.25), PFE: 30.59 (+0.27), HAL: 48.54 (-0.69), BAC: 17.14 (+0.05), EMC: 30.39 (+0.01), DNR: 10.01 (unch), TWTR: 40.61 (+0.14), BHI: 63.55 (-1.68)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Zoetis 2015 Guidance Misses As Buyout Theories Abound
at Investor's Business Daily - Tue Nov 18, 2:15PM CST
Animal-health giant Zoetis (ZTS) offered 2015 guidance below the Street's consensus along with longer-term financial goals at its analyst day Tuesday. After a brief halt in trading for the early-afternoon announcement, the stock was down more than 1%...
AGN: 213.37 (+4.17), ZTS: 44.19 (-0.04), ABT: 43.70 (-0.01), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), PFE: 30.59 (+0.27)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Cramer: Zoetis Defends Against Takeover; GoPro Is Going Higher
at The Street - Tue Nov 18, 9:55AM CST
TheStreet's Jim Cramer says Zoetis' $500 million buyback is a defense tactic to prevent a takeover, while shares of GoPro are headed higher despite its secondary offering.
ZTS: 44.19 (-0.04), GPRO: 84.10 (+2.60), VRX: 141.94 (+5.21), PFE: 30.59 (+0.27)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.70 (-0.01), PFE: 30.59 (+0.27), AZN: 73.98 (+1.48), LLY: 67.78 (+0.49), GSK: 46.28 (+0.40), NVS: 95.58 (+1.20)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 18, 8:29AM CST
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 269.60 (+21.66), PFE: 30.59 (+0.27), TEVA: 57.23 (-0.01)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.22 (+0.62), PFE: 30.59 (+0.27), MRK: 59.89 (+0.43), LLY: 67.78 (+0.49), SNY: 48.36 (+0.82), MNKD: 6.60 (+0.34)
Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research
PR Newswire - Tue Nov 18, 8:00AM CST
Sanguine Biosciences - a biotechnology company focusing on technology development, patient engagement and study recruitment - will use its proprietary mobile application and direct-to-patient platform, called Sangre, to help Pfizer Inc. find and recruit people diagnosed with Congenital Insensitivity to Pain (CIP) and their family members to participate in voluntary research, which will be used to help potentially identify DNA mutations and hopefully aid in informing the development of potential therapies for chronic pain.
PFE: 30.59 (+0.27)
TRUMENBA(R) (Meningococcal Group B Vaccine) is Now Available
Business Wire - Tue Nov 18, 7:30AM CST
Pfizer Inc. (NYSE
FE) announced today that TRUMENBA(R) (Meningococcal Group B Vaccine), the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
PFE: 30.59 (+0.27)
Vipshop Leads 4 Top Stocks With Bolting RS Lines
at Investor's Business Daily - Tue Nov 18, 7:02AM CST
Going with the flow is all well and good, but rising head and shoulders above the crowd is a sign of a solid stock. Today's Screen of the Day features four companies that have bolting Relative Strength lines. An RS line tracks how a stock is doing...
ZTS: 44.19 (-0.04), ABT: 43.70 (-0.01), VIPS: 23.71 (-0.28), BIDU: 242.75 (-1.40), PFE: 30.59 (+0.27), JMEI: 23.21 (-0.43), COST: 139.21 (+0.74), IDXX: 149.97 (+0.56), LITB: 7.64 (-0.13), BABA: 110.81 (-3.44)
Wall Street Breakfast: Abe Delays Sales Tax Hike
Wall Street Breakfast - Seeking Alpha - Tue Nov 18, 5:31AM CST
Economy Japanese Prime Minister Shinzo Abe says he will delay a sales tax rise and call a snap election, a day after data showed the economy had contracted for two successive quarters, dragged down by a rise in the consumption tax in April....
RAI: 65.30 (+0.60), GOMO: 6.20 (-0.03), FB: 74.34 (+0.10), PFE: 30.59 (+0.27), SNE: 21.26 (+1.00), INTC: 34.71 (+0.47), GOOG: 535.03 (-1.48), T: 35.72 (-0.13), SPY: 205.55 (+1.18), QQQ: 103.68 (+0.77), TRP: 49.57 (-0.53), S: 4.76 (-0.15), AZN: 73.98 (+1.48), EDGW: 7.97 (+0.58), GOOGL: 544.51 (-2.13), ACCO: 8.89 (-0.08)
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 18, 4:40AM CST
MBI: 10.26 (+0.01), GD: 143.93 (+1.88), UPL: 22.27 (-0.16), BBRY: 10.76 (-0.18), RYAM: 25.86 (unch), OSTK: 23.82 (+0.01), INTC: 34.71 (+0.47), PTEN: 20.26 (-0.37), PCP: 230.96 (+4.16), JNJ: 108.83 (+0.53), SLM: 9.87 (-0.03), PWE: 4.21 (+0.04), TRQ: 3.57 (+0.02), IBM: 161.89 (-2.27), XCO: 3.10 (+0.03), BP: 41.19 (+0.29), NYT: 12.78 (+0.09), ORI: 15.09 (+0.03), NAVI: 20.87 (+0.06), DXM: 8.42 (+0.02), SD: 3.76 (+0.05), NEU: 387.88 (+3.22), NYCB: 15.86 (-0.04), PFE: 30.59 (+0.27), KW: 26.07 (-0.13), EDU: 22.42 (-0.38), WFC: 53.27 (-0.17), BYI: 82.79 (+0.18), CSX: 36.67 (unch), LRN: 12.43 (-0.30), NTP: 4.88 (-0.03), USB: 43.98 (+0.18), CRESY: 11.75 (+0.24), BWINB: 25.89 (+0.12), BCE: 47.98 (+0.64), USG: 28.08 (+0.30), STL: 13.80 (-0.01), BRK.B: 145.81 (+0.44), BRK.A: 218,868.00 (+328.00), RFP: 18.19 (unch), HOLX: 26.64 (+0.27)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), GERN: 3.17 (+0.19), MRK: 59.89 (+0.43), AZN: 73.98 (+1.48), PFE: 30.59 (+0.27), INCY: 69.64 (-0.06), BMY: 58.70 (+0.27), CTIC: 2.28 (+0.04), NVS: 95.58 (+1.20)
US, German drugmakers team up on cancer medicines
By LINDA A. JOHNSON - AP - Mon Nov 17, 2:51PM CST
TRENTON, N.J. (AP) — Pfizer said Monday that it will partner with German drug and chemical maker Merck in developing potential cancer drugs in a hot new medication class that harnesses the body's immune system to fight cancer.
PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Will Lower Guidance Hurt Pfizer (PFE) Stock Today?
at The Street - Mon Nov 17, 1:04PM CST
Pfizer (PFE) shares are up after the company lowered its full year 2014 earnings guidance in the wake of its $850 million deal with Merck KGaA.
PFE: 30.59 (+0.27)
Puma Biotechnology Falls on Disappointing Neratinib Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 1:04PM CST
Puma Biotechnology, Inc.'s (PBYI) neratinib failed to show significant improvement in progression free survival (PFS) as a first-line treatment of HER2-positive breast cancer.
BIIB: 305.56 (+3.14), PFE: 30.59 (+0.27), PBYI: 223.00 (+11.45)
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 46.70 (+0.06), PFE: 30.59 (+0.27), BIOD: 1.61 (+0.02)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 43.53 (+0.61), KMI: 40.41 (+0.16), GE: 27.01 (+0.40), F: 15.50 (-0.04), ABX.TO: 15.04 (+0.97), K.TO: 3.37 (+0.32), ABX: 13.29 (+0.82), KGC: 2.96 (+0.25), PFE: 30.59 (+0.27), HAL: 48.54 (-0.69), BAC: 17.14 (+0.05), EMC: 30.39 (+0.01), DNR: 10.01 (unch), TWTR: 40.61 (+0.14), BHI: 63.55 (-1.68)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were up at the close of trading:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Zoetis 2015 Guidance Misses As Buyout Theories Abound
at Investor's Business Daily - Tue Nov 18, 2:15PM CST
Animal-health giant Zoetis (ZTS) offered 2015 guidance below the Street's consensus along with longer-term financial goals at its analyst day Tuesday. After a brief halt in trading for the early-afternoon announcement, the stock was down more than 1%...
AGN: 213.37 (+4.17), ZTS: 44.19 (-0.04), ABT: 43.70 (-0.01), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), PFE: 30.59 (+0.27)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Cramer: Zoetis Defends Against Takeover; GoPro Is Going Higher
at The Street - Tue Nov 18, 9:55AM CST
TheStreet's Jim Cramer says Zoetis' $500 million buyback is a defense tactic to prevent a takeover, while shares of GoPro are headed higher despite its secondary offering.
ZTS: 44.19 (-0.04), GPRO: 84.10 (+2.60), VRX: 141.94 (+5.21), PFE: 30.59 (+0.27)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.70 (-0.01), PFE: 30.59 (+0.27), AZN: 73.98 (+1.48), LLY: 67.78 (+0.49), GSK: 46.28 (+0.40), NVS: 95.58 (+1.20)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
JNJ: 108.83 (+0.53), BAX: 72.58 (+0.58), PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - Tue Nov 18, 8:29AM CST
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 269.60 (+21.66), PFE: 30.59 (+0.27), TEVA: 57.23 (-0.01)
Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST
NVO: 44.22 (+0.62), PFE: 30.59 (+0.27), MRK: 59.89 (+0.43), LLY: 67.78 (+0.49), SNY: 48.36 (+0.82), MNKD: 6.60 (+0.34)
Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research
PR Newswire - Tue Nov 18, 8:00AM CST
Sanguine Biosciences - a biotechnology company focusing on technology development, patient engagement and study recruitment - will use its proprietary mobile application and direct-to-patient platform, called Sangre, to help Pfizer Inc. find and recruit people diagnosed with Congenital Insensitivity to Pain (CIP) and their family members to participate in voluntary research, which will be used to help potentially identify DNA mutations and hopefully aid in informing the development of potential therapies for chronic pain.
PFE: 30.59 (+0.27)
TRUMENBA(R) (Meningococcal Group B Vaccine) is Now Available
Business Wire - Tue Nov 18, 7:30AM CST
Pfizer Inc. (NYSE
FE) announced today that TRUMENBA(R) (Meningococcal Group B Vaccine), the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States. PFE: 30.59 (+0.27)
Vipshop Leads 4 Top Stocks With Bolting RS Lines
at Investor's Business Daily - Tue Nov 18, 7:02AM CST
Going with the flow is all well and good, but rising head and shoulders above the crowd is a sign of a solid stock. Today's Screen of the Day features four companies that have bolting Relative Strength lines. An RS line tracks how a stock is doing...
ZTS: 44.19 (-0.04), ABT: 43.70 (-0.01), VIPS: 23.71 (-0.28), BIDU: 242.75 (-1.40), PFE: 30.59 (+0.27), JMEI: 23.21 (-0.43), COST: 139.21 (+0.74), IDXX: 149.97 (+0.56), LITB: 7.64 (-0.13), BABA: 110.81 (-3.44)
Wall Street Breakfast: Abe Delays Sales Tax Hike
Wall Street Breakfast - Seeking Alpha - Tue Nov 18, 5:31AM CST
Economy Japanese Prime Minister Shinzo Abe says he will delay a sales tax rise and call a snap election, a day after data showed the economy had contracted for two successive quarters, dragged down by a rise in the consumption tax in April....
RAI: 65.30 (+0.60), GOMO: 6.20 (-0.03), FB: 74.34 (+0.10), PFE: 30.59 (+0.27), SNE: 21.26 (+1.00), INTC: 34.71 (+0.47), GOOG: 535.03 (-1.48), T: 35.72 (-0.13), SPY: 205.55 (+1.18), QQQ: 103.68 (+0.77), TRP: 49.57 (-0.53), S: 4.76 (-0.15), AZN: 73.98 (+1.48), EDGW: 7.97 (+0.58), GOOGL: 544.51 (-2.13), ACCO: 8.89 (-0.08)
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - Tue Nov 18, 4:40AM CST
MBI: 10.26 (+0.01), GD: 143.93 (+1.88), UPL: 22.27 (-0.16), BBRY: 10.76 (-0.18), RYAM: 25.86 (unch), OSTK: 23.82 (+0.01), INTC: 34.71 (+0.47), PTEN: 20.26 (-0.37), PCP: 230.96 (+4.16), JNJ: 108.83 (+0.53), SLM: 9.87 (-0.03), PWE: 4.21 (+0.04), TRQ: 3.57 (+0.02), IBM: 161.89 (-2.27), XCO: 3.10 (+0.03), BP: 41.19 (+0.29), NYT: 12.78 (+0.09), ORI: 15.09 (+0.03), NAVI: 20.87 (+0.06), DXM: 8.42 (+0.02), SD: 3.76 (+0.05), NEU: 387.88 (+3.22), NYCB: 15.86 (-0.04), PFE: 30.59 (+0.27), KW: 26.07 (-0.13), EDU: 22.42 (-0.38), WFC: 53.27 (-0.17), BYI: 82.79 (+0.18), CSX: 36.67 (unch), LRN: 12.43 (-0.30), NTP: 4.88 (-0.03), USB: 43.98 (+0.18), CRESY: 11.75 (+0.24), BWINB: 25.89 (+0.12), BCE: 47.98 (+0.64), USG: 28.08 (+0.30), STL: 13.80 (-0.01), BRK.B: 145.81 (+0.44), BRK.A: 218,868.00 (+328.00), RFP: 18.19 (unch), HOLX: 26.64 (+0.27)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.83 (+0.53), GILD: 103.71 (+3.27), GERN: 3.17 (+0.19), MRK: 59.89 (+0.43), AZN: 73.98 (+1.48), PFE: 30.59 (+0.27), INCY: 69.64 (-0.06), BMY: 58.70 (+0.27), CTIC: 2.28 (+0.04), NVS: 95.58 (+1.20)
US, German drugmakers team up on cancer medicines
By LINDA A. JOHNSON - AP - Mon Nov 17, 2:51PM CST
TRENTON, N.J. (AP) — Pfizer said Monday that it will partner with German drug and chemical maker Merck in developing potential cancer drugs in a hot new medication class that harnesses the body's immune system to fight cancer.
PFE: 30.59 (+0.27), BMY: 58.70 (+0.27)
Will Lower Guidance Hurt Pfizer (PFE) Stock Today?
at The Street - Mon Nov 17, 1:04PM CST
Pfizer (PFE) shares are up after the company lowered its full year 2014 earnings guidance in the wake of its $850 million deal with Merck KGaA.
PFE: 30.59 (+0.27)
Puma Biotechnology Falls on Disappointing Neratinib Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 1:04PM CST
Puma Biotechnology, Inc.'s (PBYI) neratinib failed to show significant improvement in progression free survival (PFS) as a first-line treatment of HER2-positive breast cancer.
BIIB: 305.56 (+3.14), PFE: 30.59 (+0.27), PBYI: 223.00 (+11.45)
